uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update
uniQure N.V. - Ordinary Shares (QURE)
Last uniqure n.v. - ordinary shares earnings: 4/29 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
uniqure.com/investors-newsroom/overview.php
Company Research
Source: GlobeNewswire
~ Announced pivotal topline data from Phase I/II study of AMT-130 in Huntington’s disease met its primary and key secondary endpoints, demonstrating statistically significant slowing of disease progression at 36 months and supportive trends across key clinical and biomarker endpoints ~ ~ Preliminary feedback from FDA at a recent pre-Biologics License Application (BLA) meeting for AMT-130 indicated a key shift from prior regulatory communications; uniQure plans to urgently interact with the FDA to define next steps ~ ~ Advanced enrollment of Phase I/IIa study of AMT-260 in mesial temporal lobe epilepsy, with additional clinical data expected in the first half of 2026 ~ ~ Presented initial data from Phase I/IIa study of AMT-191 in Fabry disease showing sustained increases in a-gal enzyme activity in patients with Fabry disease; additional clinical data expected in the first half of 2026 ~ ~ Raised approximately $323.7 million in net proceeds in an upsized public follow-on offering,
Show less
Read more
Impact Snapshot
Event Time:
QURE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
QURE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
QURE alerts
High impacting uniQure N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
QURE
News
- QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the FirmPR Newswire
- uniQure (NASDAQ:QURE) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $53.00 price target on the stock.MarketBeat
- Rare Stock Picks In November 2025 - From 14 Discerning Analysts [Seeking Alpha]Seeking Alpha
- uniQure Provides Regulatory Update on AMT-130 for Huntington’s DiseaseGlobeNewswire
- QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the FirmGlobeNewswire
QURE
Earnings
- 11/10/25 - Miss
QURE
Sec Filings
- 12/4/25 - Form 8-K
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- QURE's page on the SEC website